Held by 2 specialist biotech funds
# Signal Note: Casdin Capital Initiates 10x Genomics Position Casdin's $22.8M entry into TXG signals conviction in single-cell analysis tools as genomics infrastructure matures. 10x's core strengths in spatial transcriptomics and multiomics platforms remain foundational for target discovery and biomarker validation across oncology and immunology pipelines, particularly as cell-level resolution becomes standard in drug development. No near-term catalyst evident; position likely reflects longer-term thesis on consolidation of genomics workflows around established platforms.